IPP Bureau
Laurus receives license to manufacture and market 2DG
By IPP Bureau - July 04, 2021
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
Phyto Chem India posts loss of Rs. 18.57 lakhs in Q4
By IPP Bureau - July 04, 2021
The company has reported total income of Rs.45.29 crores during the 12 months period ended March 31, 2021
Kwality Pharmaceuticals Q4FY21 consolidated PAT higher at Rs. 8.14 Cr
By IPP Bureau - July 04, 2021
The company reported total income of Rs.263.60 crores during the 12 months period ended March 31, 2021
Solara announces restoration of CEP for ranitidine hydrochloride
By IPP Bureau - July 03, 2021
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
Samrat Pharmachem reports Q4 FY21 PAT at Rs. 1.55 Cr
By IPP Bureau - July 02, 2021
The company has posted net profit / (loss) of Rs.5.33 crores for the 12 months period ended March 31, 2021
Sandu Pharmaceuticals Q4FY21 PAT at Rs. 46.14 lakhs
By IPP Bureau - July 02, 2021
The company has posted net profit of Rs.1.09 crores for the 12 months period ended March 31, 2021
Lupin receives tentative U.S. FDA approval for Dolutegravir, Lamivudine and TLD tablets
By IPP Bureau - July 01, 2021
TLD is recommended by WHO, USAID, and PEPFAR as a preferred first-line treatment regimen for the treatment of HIV in adults and pediatric patients weighing at least 35 kg
Triastek closes US $50 Mn Series B Financing
By IPP Bureau - July 01, 2021
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
Sun Pharma launches 'Sunkalp' on National Doctors' Day
By IPP Bureau - July 01, 2021
Sun Pharma has committed Rs. 100 crores towards these initiatives
Zydus applies to the DCGI for EUA to launch ZyCoV-D
By IPP Bureau - July 01, 2021
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
Aarey Drugs and Pharmaceuticals Q4FY21 PAT at Rs. 1.40 Cr
By IPP Bureau - June 30, 2021
The company has reported total income of Rs.355.43 crores during FY 2020-21
Pharma majors collaborate for clinical trial of Molnupiravir for COVID-19
By IPP Bureau - June 30, 2021
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
Dr. Reddy's announces commercial launch of 2DG
By IPP Bureau - June 29, 2021
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's
Strides completes EU GMP inspection at Puducherry facility
By IPP Bureau - June 29, 2021
The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection
Lonza to expand API manufacturing facility in Nansha, China
By IPP Bureau - June 28, 2021
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
